Modality
Small Molecule
MOA
PD-1i
Target
IL-13
Pathway
Innate Imm
WilmsMDS
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Jul 2029
Phase 1Current
NCT04994874
1,375 pts·MDS
2024-10→2026-05·Active
NCT05750723
2,901 pts·Wilms
2021-07→2029-07·Not yet recruiting
4,276 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-222mo awayInterim· MDS
2029-07-033.3y awayInterim· Wilms
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Not yet…
P1
Active
Catalysts
Interim
2026-05-22 · 2mo away
MDS
Interim
2029-07-03 · 3.3y away
Wilms
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04994874 | Phase 1 | MDS | Active | 1375 | Biomarker |
| NCT05750723 | Phase 1 | Wilms | Not yet recr... | 2901 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Elrarapivir | Iovance | Phase 2 | IL-13 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R |